PHAT (Phathom Pharmaceuticals) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAT Phathom Pharmaceuticals Inc PHAT
39 GF Score
Price $9.18
GF Value $24.85
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

PHAT
39GF Score
Phathom Pharmaceuticals Inc PHAT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Phathom Pharmaceuticals (PHAT) Overvalued in 2026?

Based on GuruFocus' analysis, Phathom Pharmaceuticals stock appears to be undervalued. The current stock price of $9.18 is trading 63.1% below its estimated GF Value™ of $24.85. GuruFocus considers Phathom Pharmaceuticals to be Possible Value Trap.

Key valuation signals for PHAT:

  • Dividends Received:
  • GF Value™: $24.85 vs. price of $9.18 (63.1% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the PHAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
39GF Score

Get the complete analysis for PHAT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.18
Price
$24.85
GF Value